Patents by Inventor Victoria Gavrias

Victoria Gavrias has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Control of gene expression in eukaryotic cells
    Patent number: 7202085
    Abstract: DNA constructs and other compositions and methods for controlling gene expression in eukaryotic cells and organisms are derived from bacterial quorum sensing systems. One or more cis elements from the luxI promoter (“lux box”) or a functionally similar sequence are incorporated in a eukaryotic promoter. A receptor protein from the LuxR family of transcriptional regulators, upon binding an acylated homoserine lactone (AHL) compound, interacts with the lux box, modulating the activity of the promoter.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: April 10, 2007
    Assignee: Calgene LLC
    Inventors: Tim N. Oulmassov, Kevin E. McBride, Paula C. Miller, John C. Anderson, Lyle D. Crossland, Thomas H. Adams, Barbara A. Qurollo, Victoria Gavrias
  • Control of gene expression in eukaryotic cells
    Publication number: 20050227285
    Abstract: DNA constructs and other compositions and methods for controlling gene expression in eukaryotic cells and organisms are derived from bacterial quorum sensing systems. One or more cis elements from the luxI promoter (“lux box”) or a functionally similar sequence are incorporated in a eukaryotic promoter. A receptor protein from the LuxR family of transcriptional regulators, upon binding an acylated homoserine lactone (AHL) compound, interacts with the lux box, modulating the activity of the promoter.
    Type: Application
    Filed: June 3, 2005
    Publication date: October 13, 2005
    Inventors: Tim Oulmassov, Kevin McBride, Paula Miller, John Anderson, Lyle Crossland, Thomas Adams, Barbara Qurollo, Victoria Gavrias
  • Control of gene expression in eukaryotic cells
    Patent number: 6943243
    Abstract: DNA constructs and other compositions and methods for controlling gene expression in eukaryotic cells and organisms are derived from bacterial quorum sensing systems. One or more cis elements from the luxI promoter (“lux box”) or a functionally similar sequence are incorporated in a eukaryotic promoter. A receptor protein from the LuxR family of transcriptional regulators, upon binding an acylated homoserine lactone (AHL) compound, interacts with the lux box, modulating the activity of the promoter.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: September 13, 2005
    Assignee: Calgene LLC
    Inventors: Tim N. Oulmassov, Kevin E. McBride, Paula C. Miller, John C. Anderson, Lyle D. Crossland, Thomas H. Adams, Barbara A. Qurollo, Victoria Gavrias
  • Control of gene expression in eukaryotic cells
    Publication number: 20030224483
    Abstract: DNA constructs and other compositions and methods for controlling gene expression in eukaryotic cells and organisms are derived from bacterial quorum sensing systems. One or more cis elements from the luxI promoter (“lux box”) or a functionally similar sequence are incorporated in a eukaryotic promoter. A receptor protein from the LuxR family of transcriptional regulators, upon binding an acylated homoserine lactone (AHL) compound, interacts with the lux box, modulating the activity of the promoter.
    Type: Application
    Filed: February 6, 2003
    Publication date: December 4, 2003
    Inventors: Tim N. Oulmassov, Kevin E. McBride, Paula C. Miller, John C. Anderson, Lyle D. Crossland, Thomas H. Adams, Barbara A. Qurollo, Victoria Gavrias
  • Control of gene expression in eukaryotic cells
    Patent number: 6518066
    Abstract: DNA constructs and other compositions and methods for controlling gene expression in eukaryotic cells and organisms are derived from bacterial quorum sensing systems. One or more cis elements from the luxI promoter (“lux box”) or a functionally similar sequence are incorporated in a eukaryotic promoter. A receptor protein from the LuxR family of transcriptional regulators, upon binding an acylated homoserine lactone (AHL) compound, interacts with the lux box, modulating the activity of the promoter.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: February 11, 2003
    Assignee: Calgene LLC
    Inventors: Tim N. Oulmassov, Kevin E. McBride, Paula C. Miller, John C. Anderson, Lyle D. Crossland, Thomas H. Adams, Barbara A. Qurollo, Victoria Gavrias
  • Essential fungal genes and their use
    Patent number: 6514715
    Abstract: Disclosed are essential Aspergillus polypeptides and genes (AN97, AN17, AN80, and AN85), as well as homologs thereof, which can be used to identify antifungal agents for treating fungal infections such as aspergillosis.
    Type: Grant
    Filed: July 23, 2001
    Date of Patent: February 4, 2003
    Assignee: Millenium Pharmaceuticals, Inc.
    Inventors: Yigal Koltin, Victoria Gavrias
  • Essential fungal genes and their use
    Patent number: 6465198
    Abstract: Disclosed are essential Aspergillus polypeptides and genes (AN97, AN17, AN80, and AN85), as well as homologs thereof, which can be used to identify antifungal agents for treating fungal infections such as aspergillosis.
    Type: Grant
    Filed: July 23, 2001
    Date of Patent: October 15, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Yigal Koltin, Victoria Gavrias
  • Essential fungal genes and their use
    Patent number: 6461826
    Abstract: Disclosed are essential Aspergillus polypeptides and genes (AN97, AN17, AN80, and AN85), as well as homologs thereof, which can be used to identify antifungal agents for treating fungal infections such as aspergillosis.
    Type: Grant
    Filed: July 23, 2001
    Date of Patent: October 8, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Yigal Koltin, Victoria Gavrias
  • Essential fungal genes and their use
    Publication number: 20020142363
    Abstract: Abstract of the Disclosure Disclosed are essential Aspergillus polypeptides and genes (AN97, AN17, AN80, and AN85), as well as homologs thereof, which can be used to identify antifungal agents for treating fungal infections such as aspergillosis.
    Type: Application
    Filed: July 23, 2001
    Publication date: October 3, 2002
    Applicant: Millennium Pharmaceutical, Inc.
    Inventors: Yigal Koltin, Victoria Gavrias
  • Essential fungal genes and their use
    Publication number: 20020119509
    Abstract: Disclosed are essential Aspergillus polypeptides and genes (AN97, AN17, AN80, and AN85), as well as homologs thereof, which can be used to identify antifungal agents for treating fungal infections such as aspergillosis.
    Type: Application
    Filed: July 23, 2001
    Publication date: August 29, 2002
    Applicant: Millennium Pharmaceuticals, Inc., a Massachusetts corporation
    Inventors: Yigal Koltin, Victoria Gavrias
  • High throughput screening for inhibitors of fatty acid, ergosterol, sphingolipid, or phospholipid synthesis in fungi
    Publication number: 20020037495
    Abstract: Methods for identifying compounds that are inhibitors of fatty acid, ergosterol, sphingolipid, or phospholipid synthesis are disclosed. Such compounds can be derivatized to produce antifungal agents, which can be used in methods of treating fungal infections (e.g., in humans, animals, and plants). The disclosed methods allow for high throughput screening of libraries of test compounds.
    Type: Application
    Filed: March 23, 2001
    Publication date: March 28, 2002
    Inventors: Juan Antonio Gutierrez, Christine Ellen Bulawa, Ronald K. Blackman, Victoria Gavrias
  • Essential fungal genes and their use
    Patent number: 6280963
    Abstract: Disclosed are essential Aspergillus polypeptides and genes (AN97, AN17, AN80, and AN85), as well as homologs of, which can be used to identify antifungal agents for treating fungal infections such as aspergillosis.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: August 28, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Yigal Koltin, Victoria Gavrias
  • Identification of essential survival genes
    Patent number: 5976828
    Abstract: A method for identifying a strain having a conditional lethal mutation which is essential for survival when strain is incubated under restrictive growth conditions, and methods of identifying gene products and gene functions thereof.
    Type: Grant
    Filed: October 13, 1998
    Date of Patent: November 2, 1999
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: William Timberlake, Victoria Gavrias
  • Identification of essential survival genes
    Patent number: 5821076
    Abstract: A method for identifying a strain having a conditional lethal mutation which is essential for survival when strain is incubated under restrictive growth conditions, and methods of identifying gene products and gene functions thereof.
    Type: Grant
    Filed: March 19, 1998
    Date of Patent: October 13, 1998
    Assignee: Millennium Pharmaceuticals Inc.
    Inventors: William Timberlake, Victoria Gavrias
  • Identification of essential survival genes
    Patent number: 5756305
    Abstract: A method for identifying a strain having a conditional lethal mutation which is essential for survival when strain is incubated under restrictive growth conditions, and methods of identifying gene products and gene functions thereof.
    Type: Grant
    Filed: May 6, 1996
    Date of Patent: May 26, 1998
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: William Timberlake, Victoria Gavrias